FIELD: medicine.
SUBSTANCE: use of a nanoparticle or an aggregate of nanoparticles for the prevention or treatment of a neurological disease or at least one of its symptoms in a subject without affecting the nanoparticle or the aggregate of nanoparticles with an electric field or any other external source of activation is disclosed. Material of the nanoparticle or the aggregate of nanoparticles is selected from conductive material selected from Tl, Po, Ag, Pd, Ir, Pt, and/or Au and organic material having adjacent sp2-hybridized carbon centers in its structure; and insulating material selected from Al2O3, LaAlO3, La2O3, SiO2, SnO2, Ta2O5, ReO2, ZrO2, HfO2, and diamond-like carbon. In this case, i) a median size of a core of the nanoparticle or the aggregate of nanoparticles of a population is at least 30 nm, when material is conductive material, and ii) the core of the nanoparticle or the aggregate of nanoparticles is coated with biocompatible coating, iii) biocompatible coating providing a negative surface charge is selected from phosphate, dicarboxylic acid, succinic acid, or sulfate, and biocompatible coating providing a neutral surface charge is selected from an agent including a functional group selected from alcohol (R-OH), aldehyde (R-COH), ketone (R-CO-R), composite ester (R-COOR), acid (R-COOH), thiol (R-SH), saccharide, anhydride (RCOOOC-R), and pyrrole. The use of a composition including the above-described particles and/or aggregates of nanoparticles, and a pharmaceutically acceptable carrier for the prevention or treatment of a neurological disease or at least one of its symptoms in a subject are also disclosed.
EFFECT: group of inventions provides prevention or treatment of a neurological disease or at least one of its symptoms without affecting a nanoparticle or an aggregate of nanoparticles with an electric field.
6 cl, 21 dwg, 8 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
NANOPARTICLES FOR USE IN INCREASING BRAIN WORKING CAPACITY OR IN STRESS TREATMENT | 2018 |
|
RU2782384C2 |
COMPOSITION BASED ON NANOPARTICLES WITH IMPROVED PENETRATION THROUGH MUCOUS MEMBRANES | 2013 |
|
RU2598627C2 |
RESTORATION OF THE SENSORIMOTOR FUNCTION USING A NEUROPROSTHETIC SYSTEM AND METHOD FOR IMPLEMENTATION THEREOF | 2020 |
|
RU2772637C2 |
PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
ISOINDOLINE COMPOSITIONS AND METHODS OF TREATING NEURODEGENERATIVE DISEASE | 2015 |
|
RU2692258C2 |
PEPTIDE CONJUGATED PARTICLES | 2014 |
|
RU2685186C2 |
NON-MEDUCATIONAL METHOD OF TREATMENT OF ADYNAMIC DEPRESSIONS | 2022 |
|
RU2801161C1 |
DONECOPRID AS A NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGERATIVE DISEASES | 2019 |
|
RU2800802C2 |
USING MESENCHYMAL AND NEURONAL MARKER EXPRESSING STEM CELLS AND THEIR COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES (VERSIONS) | 2017 |
|
RU2742828C2 |
USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
Authors
Dates
2022-09-13—Published
2018-12-18—Filed